Review Article | Published:

Polymer–drug conjugate therapeutics: advances, insights and prospects

Nature Reviews Drug Discoveryvolume 18pages273294 (2019) | Download Citation

Abstract

Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several conjugates successfully translated into clinical practice. The conjugation of therapeutic agents to polymeric carriers, such as polyethylene glycol, offers several advantages, including improved drug solubilization, prolonged circulation, reduced immunogenicity, controlled release and enhanced safety. In this Review, we discuss the rational design, physicochemical characteristics and recent advances in the development of different classes of polymer–drug conjugates, including polymer–protein and polymer–small-molecule drug conjugates, dendrimers, polymer nanoparticles and multifunctional systems. Current obstacles hampering the clinical translation of polymer–drug conjugate therapeutics and future prospects are also presented.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. C 51, 135–153 (1975).

  2. 2.

    Kopecek, J. & Kopeckova, P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev. 62, 122–149 (2010).

  3. 3.

    Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347–360 (2003).

  4. 4.

    Nagle, T., Berg, C., Nassr, R. & Pang, K. The further evolution of biotech. Nat. Rev. Drug Discov. 2, 75–79 (2003).

  5. 5.

    Caliceti, P. & Veronese, F. M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55, 1261–1277 (2003).

  6. 6.

    Tong, R. & Cheng, J. Anticancer polymeric nanomedicines. Polym. Rev. 47, 345–381 (2007).

  7. 7.

    Canalle, L. A., Lowik, D. W. & van Hest, J. C. Polypeptide-polymer bioconjugates. Chem. Soc. Rev. 39, 329–353 (2010).

  8. 8.

    Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655–672 (2014).

  9. 9.

    Abuchowski, A., van Es, T., Palczuk, N. C. & Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578–3581 (1977).

  10. 10.

    Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T. & Davis, F. F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582–3586 (1977).

  11. 11.

    Alconcel, S. N. S., Baas, A. S. & Maynard, H. D. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym. Chem. 2, 1442–1448 (2011).

  12. 12.

    Hershfield, M. S. et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med. 316, 589–596 (1987).

  13. 13.

    Ulbrich, K. et al. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem. Rev. 116, 5338–5431 (2016).

  14. 14.

    Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537–550 (2010).

  15. 15.

    Turecek, P. L., Bossard, M. J., Schoetens, F. & Ivens, I. A. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J. Pharm. Sci. 105, 460–475 (2016).

  16. 16.

    Graham, M. L. PEGaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55, 1293–1302 (2003).

  17. 17.

    Peters, B. G., Goeckner, B. J., Ponzillo, J. J., Velasquez, W. S. & Wilson, A. L. PEGaspargase versus asparaginase in adult all: a pharmacoeconomic assessment. Formulary 30, 388–393 (1995).

  18. 18.

    Macdougall, I. C. et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 1, 1211–1215 (2006).

  19. 19.

    Curran, M. P. & McCormack, P. L. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 68, 1139–1156 (2008).

  20. 20.

    Bezditko, N., Iakovlieva, L., Mishchenko, O., Gerasymova, O. & Kyrychenko, O. Pharmacoeconomic aspects of use of erythropoietin drugs in patients on hemodialysis in ukraine. Value Health 15, A459 (2012).

  21. 21.

    Wang, Y. S. et al. Structural and biological characterization of PEGylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54, 547–570 (2002).

  22. 22.

    Rajender Reddy, K., Modi, M. W. & Pedder, S. Use of PEGinterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54, 571–586 (2002).

  23. 23.

    Yang, B. B. & Kido, A. Pharmacokinetics and pharmacodynamics of PEGfilgrastim. Clin. Pharmacokinet. 50, 295–306 (2011).

  24. 24.

    Deeks, E. D. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs 73, 75–97 (2013).

  25. 25.

    Kharitonenkov, A. & Adams, A. C. Inventing new medicines: the FGF21 story. Mol. Metab. 3, 221–229 (2014).

  26. 26.

    So, W. Y. & Leung, P. S. Fibroblast growth factor 21 as an emerging therapeutic target for type 2 diabetes mellitus. Med. Res. Rev. 36, 672–704 (2016).

  27. 27.

    Sanyal, A. et al. BMS-986036 (PEGylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study. J. Hepatol. 66, S89–S90 (2017).

  28. 28.

    Charles, E. D. et al. A phase 1 study of BMS-986036 (PEGylated FGF21) in healthy obese subjects. Hepatology 64, 546A (2016).

  29. 29.

    Charles, E. D., Tetri, B. A., Luo, Y., Wu, C. K. & Christian, R. A phase 2 study of BMS-986036 (PEGylated FGF21) in obese adults with type 2 diabetes and a high prevalence of fatty liver. Hepatology 64, 17A (2016).

  30. 30.

    Wu, C. K., Charles, E. D., Bui, A., Christian, R. & Abu Tarif, M. Phase 1 study of BMS-986171 (PEGylated FGF21) in healthy obese subjects. Hepatology 64, 564A–565A (2016).

  31. 31.

    Huhn, R. D. et al. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin. Pharmacol. Ther. 62, 171–180 (1997).

  32. 32.

    Naing, A. et al. CD8+ T cell stimulation with PEGylated recombinant human IL-10 in the patient with advanced solid tumors — a phase I study. J. Immunother. Cancer 3, P204 (2015).

  33. 33.

    Mumm, J. B. et al. Il-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20, 781–796 (2011).

  34. 34.

    Naing, A. et al. Safety, antitumor activity, and immune activation of PEGylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J. Clin. Oncol. 34, 3562–3569 (2016).

  35. 35.

    Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680–690 (2016).

  36. 36.

    Charych, D. et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLOS ONE 12, e0179431 (2017).

  37. 37.

    Langowski, J. et al. NKTR-358: a selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders. Arthritis Rheumatol. 69, 2 (2017).

  38. 38.

    Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459–476 (2002).

  39. 39.

    Pelegri-O’Day, E. M., Lin, E. W. & Maynard, H. D. Therapeutic protein-polymer conjugates: advancing beyond PEGylation. J. Am. Chem. Soc. 136, 14323–14332 (2014).

  40. 40.

    Smith, M. E. et al. Protein modification, bioconjugation, and disulfide bridging using bromomaleimides. J. Am. Chem. Soc. 132, 1960–1965 (2010).

  41. 41.

    Jones, M. W. et al. Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and PEGylation agents. J. Am. Chem. Soc. 134, 1847–1852 (2012).

  42. 42.

    Jones, M. W. et al. Direct peptide bioconjugation/PEGylation at tyrosine with linear and branched polymeric diazonium salts. J. Am. Chem. Soc. 134, 7406–7413 (2012).

  43. 43.

    Gauthier, M. A. & Klok, H. A. Arginine-specific modification of proteins with polyethylene glycol. Biomacromolecules 12, 482–493 (2011).

  44. 44.

    Cong, Y. et al. Site-specific PEGylation at histidine tags. Bioconjug. Chem. 23, 248–263 (2012).

  45. 45.

    Nesbitt, A. M., Stephens, S. & Chartash, E. K. in Pegylated Protein Drugs: Basic Science and Clinical Applications (ed. Veronese, F. M.) 229–254 (Birkhäuser, 2009).

  46. 46.

    Gilmore, J. M., Scheck, R. A., Esser-Kahn, A. P., Joshi, N. S. & Francis, M. B. N-terminal protein modification through a biomimetic transamination reaction. Angew. Chem. Int. Ed. 45, 5307–5311 (2006).

  47. 47.

    Obermeyer, A. C., Jarman, J. B. & Francis, M. B. N-terminal modification of proteins with o-Aminophenols. J. Am. Chem. Soc. 136, 9572–9579 (2014).

  48. 48.

    Zhang, X., Li, F., Lu, X. W. & Liu, C. F. Protein C-terminal modification through thioacid/azide amidation. Bioconjug. Chem. 20, 197–200 (2009).

  49. 49.

    Thom, J., Anderson, D., McGregor, J. & Cotton, G. Recombinant protein hydrazides: application to site-specific protein PEGylation. Bioconjug. Chem. 22, 1017–1020 (2011).

  50. 50.

    Sato, H. Enzymatic procedure for site-specific PEGylation of proteins. Adv. Drug Deliv. Rev. 54, 487–504 (2002).

  51. 51.

    Fontana, A., Spolaore, B., Mero, A. & Veronese, F. M. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv. Drug Deliv. Rev. 60, 13–28 (2008).

  52. 52.

    Popp, M. W., Dougan, S. K., Chuang, T. Y., Spooner, E. & Ploegh, H. L. Sortase-catalyzed transformations that improve the properties of cytokines. Proc. Natl Acad. Sci. USA 108, 3169–3174 (2011). Sortase-mediated, site-specific PEGylation of cytokines extends plasma half-life without compromising biological activity.

  53. 53.

    Appel, M. J. & Bertozzi, C. R. Formylglycine, a post-translationally generated residue with unique catalytic capabilities and biotechnology applications. ACS Chem. Biol. 10, 72–84 (2015).

  54. 54.

    DeFrees, S. et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16, 833–843 (2006).

  55. 55.

    Stennicke, H. R. et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 121, 2108–2116 (2013).

  56. 56.

    Wang, L., Brock, A., Herberich, B. & Schultz, P. G. Expanding the genetic code of Escherichia coli. Science 292, 498–500 (2001).

  57. 57.

    Cho, H. et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl Acad. Sci. USA 108, 9060–9065 (2011). This is the first clinical study of a PEG–protein conjugate prepared via the incorporation of an unnatural amino acid.

  58. 58.

    Mu, J. et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61, 505–512 (2012).

  59. 59.

    Bontempo, D. & Maynard, H. D. Streptavidin as a macroinitiator for polymerization: in situ protein-polymer conjugate formation. J. Am. Chem. Soc. 127, 6508–6509 (2005).

  60. 60.

    Liu, J. et al. In situ formation of protein-polymer conjugates through reversible addition fragmentation chain transfer polymerization. Angew. Chem. Int. Ed. 46, 3099–3103 (2007).

  61. 61.

    Boyer, C. et al. Well-defined protein-polymer conjugates via in situ raft polymerization. J. Am. Chem. Soc. 129, 7145–7154 (2007).

  62. 62.

    Peeler, J. C. et al. Genetically encoded initiator for polymer growth from proteins. J. Am. Chem. Soc. 132, 13575–13577 (2010).

  63. 63.

    Gao, W., Liu, W., Christensen, T., Zalutsky, M. R. & Chilkoti, A. In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc. Natl Acad. Sci. USA 107, 16432–16437 (2010).

  64. 64.

    Zhou, Y. & Kopecek, J. Biological rationale for the design of polymeric anti-cancer nanomedicines. J. Drug Target. 21, 1–26 (2013).

  65. 65.

    Lee, Y. et al. Poly(ethylene oxide sulfide): new poly(ethylene glycol) derivatives degradable in reductive conditions. Biomacromolecules 6, 24–26 (2005).

  66. 66.

    Lundberg, P. et al. Poly[(ethylene oxide)-co-(methylene ethylene oxide)]: a hydrolytically-degradable poly(ethylene oxide) platform. ACS Macro Lett. 1, 1240–1243 (2012).

  67. 67.

    Pasut, G. Polymers for protein conjugation. Polymers 6, 160–178 (2014).

  68. 68.

    Podust, V. N. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J. Control. Release 240, 52–66 (2016).

  69. 69.

    Gebauer, M. & Skerra, A. Prospects of pasylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action. Bioorg. Med. Chem. 26, 2882–2887 (2018).

  70. 70.

    Urakami, H. & Guan, Z. Living ring-opening polymerization of a carbohydrate-derived lactone for the synthesis of protein-resistant biomaterials. Biomacromolecules 9, 592–597 (2008).

  71. 71.

    Steinbach, T. & Wurm, F. R. Degradable polyphosphoester-protein conjugates: “PPEylation” of proteins. Biomacromolecules 17, 3338–3346 (2016).

  72. 72.

    Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49, 6288–6308 (2010).

  73. 73.

    Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G. & Richette, P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 9, 1319–1323 (2012).

  74. 74.

    Luxenhofer, R. et al. Poly(2-oxazoline)s as polymer therapeutics. Macromol. Rapid Commun. 33, 1613–1631 (2012).

  75. 75.

    Gangloff, N., Ulbricht, J., Lorson, T., Schlaad, H. & Luxenhofer, R. Peptoids and polypeptoids at the frontier of supra- and macromolecular engineering. Chem. Rev. 116, 1753–1802 (2016).

  76. 76.

    Hu, Y., Hou, Y., Wang, H. & Lu, H. Polysarcosine as an alternative to PEG for therapeutic protein conjugation. Bioconjug. Chem. 29, 2232–2238 (2018).

  77. 77.

    Hu, J., Wang, G., Zhao, W. & Gao, W. In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms pegasys in cancer therapy. J. Control. Release 237, 71–77 (2016).

  78. 78.

    Keefe, A. J. & Jiang, S. Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat. Chem. 4, 59–63 (2012).

  79. 79.

    Nguyen, T. H. et al. A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nat. Chem. 5, 221–227 (2013). The rational design of a heparin-mimicking polymer affords stabilization of basic FGF.

  80. 80.

    De, P., Li, M., Gondi, S. R. & Sumerlin, B. S. Temperature-regulated activity of responsive polymer-protein conjugates prepared by grafting-from via raft polymerization. J. Am. Chem. Soc. 130, 11288–11289 (2008).

  81. 81.

    Hardwicke, J. T. et al. The effect of dextrin-rhEGF on the healing of full-thickness, excisional wounds in the (db/db) diabetic mouse. J. Control. Release 152, 411–417 (2011).

  82. 82.

    Vanparijs, N. et al. Transiently responsive protein-polymer conjugates via a ‘grafting-from’ RAFT approach for intracellular co-delivery of proteins and immune-modulators. Chem. Commun. 51, 13972–13975 (2015).

  83. 83.

    Le Droumaguet, B. & Velonia, K. In situ ATRP-mediated hierarchical formation of giant amphiphile bionanoreactors. Angew. Chem. Int. Ed. 47, 6263–6266 (2008).

  84. 84.

    Jatzkewitz, H. Peptamin (glycyl-l-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z. Naturforsch. 10B, 27–31 (1955).

  85. 85.

    Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387–6392 (1986).

  86. 86.

    Stirland, D. L., Nichols, J. W., Miura, S. & Bae, Y. H. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J. Control. Release 172, 1045–1064 (2013).

  87. 87.

    Vasey, P. A. et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5, 83–94 (1999).

  88. 88.

    Seymour, L. W. et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 34, 1629–1636 (2009).

  89. 89.

    Duncan, R. & Vicent, M. J. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv. Drug Deliv. Rev. 62, 272–282 (2010).

  90. 90.

    Hoch, U., Staschen, C. M., Johnson, R. K. & Eldon, M. A. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother. Pharmacol. 74, 1125–1137 (2014).

  91. 91.

    Jameson, G. S. et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin. Cancer Res. 19, 268–278 (2013).

  92. 92.

    Perez, E. A. et al. Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (beacon): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 16, 1556–1568 (2015).

  93. 93.

    Cortes, J. et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III beacon trial. Breast Cancer Res. Treat. 165, 329–341 (2017).

  94. 94.

    Garnock-Jones, K. P. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs 75, 419–425 (2015).

  95. 95.

    Miyazaki, T. et al. NKTR-181: a novel mu-opioid analgesic with inherently low abuse potential. J. Pharmacol. Exp. Ther. 363, 104–113 (2017).

  96. 96.

    Webster, L. et al. Human abuse potential of the new opioid analgesic molecule NKTR-181 compared with oxycodone. Pain Med. 19, 307–318 (2018).

  97. 97.

    El Mehdil, D. et al. APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Mol. Immunol. 89, 115 (2017).

  98. 98.

    Roblin, D. et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm. Venereol. 95, 542–548 (2015).

  99. 99.

    Duro-Castano, A., Conejos-Sanchez, I. & Vicent, M. J. Peptide-based polymer therapeutics. Polymers 6, 515–551 (2014).

  100. 100.

    Yang, J. et al. Backbone degradable N-(2-hydroxypropyl)methacrylamide copolymer conjugates with gemcitabine and paclitaxel: impact of molecular weight on activity toward human ovarian carcinoma xenografts. Mol. Pharm. 14, 1384–1394 (2017).

  101. 101.

    Pan, H. et al. Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats. Biomaterials 34, 6528–6538 (2013).

  102. 102.

    Zhang, R., Yang, J., Sima, M., Zhou, Y. & Kopecek, J. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc. Natl Acad. Sci. USA 111, 12181–12186 (2014).

  103. 103.

    Tsai, F. T., Wang, Y. & Darensbourg, D. J. Environmentally benign CO2-based copolymers: degradable polycarbonates derived from dihydroxybutyric acid and their platinum-polymer conjugates. J. Am. Chem. Soc. 138, 4626–4633 (2016). This report describes the synthesis of a novel, water-soluble and biodegradable polymer drug carrier.

  104. 104.

    Cho, S. et al. Functionalizable hydrophilic polycarbonate, poly(5-methyl-5-(2-hydroxypropyl)aminocarbonyl-1,3-dioxan-2-one), designed as a degradable alternative for PHPMA and PEG. Macromolecules 48, 8797–8805 (2015).

  105. 105.

    Dubikovskaya, E. A., Thorne, S. H., Pillow, T. H., Contag, C. H. & Wender, P. A. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl Acad. Sci. USA 105, 12128–12133 (2008).

  106. 106.

    Wang, Y. et al. Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Adv. Drug Deliv. Rev. 110–111, 112–126 (2017).

  107. 107.

    Zhang, P., Cheetham, A. G., Lock, L. L. & Cui, H. Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug. Chem. 24, 604–613 (2013).

  108. 108.

    Birke, A., Ling, J. & Barz, M. Polysarcosine-containing copolymers: synthesis, characterization, self-assembly, and applications. Prog. Polym. Sci. 81, 163–208 (2018).

  109. 109.

    Nasongkla, N. et al. Dependence of pharmacokinetics and biodistribution on polymer architecture: effect of cyclic versus linear polymers. J. Am. Chem. Soc. 131, 3842–3843 (2009).

  110. 110.

    Etrych, T. et al. HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity. J. Control. Release 164, 346–354 (2012). In this study, the polymer–drug conjugate in vivo residence time is extended through polymer branching or increased molecular mass.

  111. 111.

    Quan, L. et al. Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano 8, 458–466 (2014).

  112. 112.

    Zhou, Y., Yang, J. & Kopecek, J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 33, 1863–1872 (2012).

  113. 113.

    England, R. M., Masia, E., Gimenez, V., Lucas, R. & Vicent, M. J. Polyacetal-stilbene conjugates — the first examples of polymer therapeutics for the inhibition of HIF-1 in the treatment of solid tumours. J. Control. Release 164, 314–322 (2012).

  114. 114.

    Chu, T. W., Yang, J. & Kopecek, J. Anti-CD20 multivalent HPMA copolymer-Fab’ conjugates for the direct induction of apoptosis. Biomaterials 33, 7174–7181 (2012). A drug-free macromolecular therapeutic comprising anti-CD20 Fab’ conjugated to a polymer carrier exhibits multivalent binding and enhanced apoptosis induction in malignant B cells.

  115. 115.

    Chu, T. W., Yang, J., Zhang, R., Sima, M. & Kopecek, J. Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis. ACS Nano 8, 719–730 (2014).

  116. 116.

    Wu, K., Liu, J., Johnson, R. N., Yang, J. & Kopecek, J. Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew. Chem. Int. Ed. 49, 1451–1455 (2010).

  117. 117.

    Tomalia, D. A. et al. A new class of polymers: starburst-dendritic macromolecules. Polym. J. 17, 117–132 (1985).

  118. 118.

    Newkome, G. R., Yao, Z., Baker, G. R. & Gupta, V. K. Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol. J. Org. Chem. 50, 2003–2004 (1985).

  119. 119.

    Sadekar, S. et al. Comparative pharmacokinetics of PAMAM-OH dendrimers and HPMA copolymers in ovarian tumor-bearing mice. Drug Deliv. Transl Res. 3, 260–271 (2013).

  120. 120.

    Nanaware-Kharade, N. et al. Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization. Bioconjug. Chem. 23, 1864–1872 (2012).

  121. 121.

    Wang, X., Inapagolla, R., Kannan, S., Lieh-Lai, M. & Kannan, R. M. Synthesis, characterization, and in vitro activity of dendrimer-streptokinase conjugates. Bioconjug. Chem. 18, 791–799 (2007).

  122. 122.

    McCarthy, T. D. et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2, 312–318 (2005).

  123. 123.

    Starpharma Holdings Limited. DEP® docetaxel positive phase 1 results; phase 2 commences. Starpharma https://www.starpharma.com/news/339 (2017).

  124. 124.

    McNerny, D. Q., Leroueil, P. R. & Baker, J. R. Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals. WIREs Nanomed. Nanobiotechnol. 2, 249–259 (2010).

  125. 125.

    Mishra, M. K. et al. Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest. ACS Nano 8, 2134–2147 (2014). Systemically administered dendrimer–drug conjugates traverse the impaired blood–brain barrier and localize in activated microglia and injured neurons, affording improved therapeutic efficacy and enhanced safety in a large animal model of brain injury.

  126. 126.

    Etrych, T. et al. Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-tumor efficacy. J. Control. Release 154, 241–248 (2011).

  127. 127.

    Restani, R. B. et al. Biocompatible polyurea dendrimers with pH-dependent fluorescence. Angew. Chem. Int. Ed. 51, 5162–5165 (2012).

  128. 128.

    Kaminskas, L. M. et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J. Control. Release 183, 18–26 (2014).

  129. 129.

    Pu, Y. et al. The anti-tumor efficiency of poly(l-glutamic acid) dendrimers with polyhedral oligomeric silsesquioxane cores. Biomaterials 34, 3658–3666 (2013).

  130. 130.

    Carnahan, M. A. & Grinstaff, M. W. Synthesis and characterization of polyether-ester dendrimers from glycerol and lactic acid. J. Am. Chem. Soc. 123, 2905–2906 (2001).

  131. 131.

    Carnahan, M. A. & Grinstaff, M. W. Synthesis and characterization of poly(glycerol−succinic acid) dendrimers. Macromolecules 34, 7648–7655 (2001).

  132. 132.

    Mintzer, M. A. & Grinstaff, M. W. Biomedical applications of dendrimers: a tutorial. Chem. Soc. Rev. 40, 173–190 (2011).

  133. 133.

    Morgan, M. T. et al. Dendritic molecular capsules for hydrophobic compounds. J. Am. Chem. Soc. 125, 15485–15489 (2003).

  134. 134.

    Iezzi, R. et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 33, 979–988 (2012).

  135. 135.

    Zhou, Z. et al. Molecularly precise dendrimer-drug conjugates with tunable drug release for cancer therapy. Angew. Chem. Int. Ed. 53, 10949–10955 (2014). The release kinetics of a therapeutic buried within a dendrimer carrier are tuned by modulating the number of generations or altering the surface chemistry.

  136. 136.

    Kim, S. H. et al. Ligand accessibility and bioactivity of a hormone-dendrimer conjugate depend on pH and pH History. J. Am. Chem. Soc. 137, 10326–10335 (2015).

  137. 137.

    Pearson, R. M. et al. Tuning the selectivity of dendron micelles through variations of the poly(ethylene glycol) corona. ACS Nano 10, 6905–6914 (2016). The cellular interaction of targeted dendron micelles is tuned via modulation of PEG corona length and targeting ligand content.

  138. 138.

    Choi, S. K. et al. Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. ACS Nano 7, 214–228 (2013). A multivalent dendrimer–vancomycin conjugate affords enhanced avidity, restoring the ability of vancomycin to bind vancomycin-resistant bacterial cell walls.

  139. 139.

    Myung, J. H., Gajjar, K. A., Saric, J., Eddington, D. T. & Hong, S. Dendrimer-mediated multivalent binding for the enhanced capture of tumor cells. Angew. Chem. Int. Ed. 50, 11769–11772 (2011).

  140. 140.

    Skwarczynski, M. et al. Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew. Chem. Int. Ed. 49, 5742–5745 (2010).

  141. 141.

    Sweet, D. M., Kolhatkar, R. B., Ray, A., Swaan, P. & Ghandehari, H. Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery. J. Control. Release 138, 78–85 (2009).

  142. 142.

    Kannan, S. et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci. Transl Med. 4, 130ra146 (2012).

  143. 143.

    Goldberg, D. S., Vijayalakshmi, N., Swaan, P. W. & Ghandehari, H. G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J. Control. Release 150, 318–325 (2011).

  144. 144.

    Wu, W., Driessen, W. & Jiang, X. Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. J. Am. Chem. Soc. 136, 3145–3155 (2014).

  145. 145.

    Li, H. J. et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl Acad. Sci. USA 113, 4164–4169 (2016).

  146. 146.

    Zhang, S. et al. Mimicking biological membranes with programmable glycan ligands self-assembled from amphiphilic janus glycodendrimers. Angew. Chem. Int. Ed. 53, 10899–10903 (2014).

  147. 147.

    Kopf, H., Joshi, R. K., Soliva, M. & Speiser, P. Study on micelle polymerization in the presence of lowmolecular-weight drugs. 1. Production and isolation of nanoparticles, residual monomer determination, physical–chemical data. Pharm. Ind. 38, 281–284 (1976).

  148. 148.

    Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615–627 (2010).

  149. 149.

    Young, C., Schluep, T., Hwang, J. & Eliasof, S. CRLX101 (formerly IT-101) — a novel nanopharmaceutical of camptothecin in clinical development. Curr. Bioact. Compd. 7, 8–14 (2011).

  150. 150.

    Markman, B. et al. A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors. J. Clin. Oncol. 34, 2 (2016).

  151. 151.

    Griset, A. P. et al. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J. Am. Chem. Soc. 131, 2469–2471 (2009).

  152. 152.

    Musumeci, T. et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. 325, 172–179 (2006).

  153. 153.

    Mu, L. & Feng, S. S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 86, 33–48 (2003).

  154. 154.

    Cabral, H. & Kataoka, K. Progress of drug-loaded polymeric micelles into clinical studies. J. Control. Release 190, 465–476 (2014).

  155. 155.

    Matsumura, Y. et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91, 1775–1781 (2004).

  156. 156.

    Svenson, S. What nanomedicine in the clinic right now really forms nanoparticles? WIREs Nanomed. Nanobiotechnol. 6, 125–135 (2014).

  157. 157.

    Cristal Therapeutics. CriPec platform. Cristal Therapeutics https://cristaltherapeutics.com/technology/cripec-platform (2015).

  158. 158.

    Hu, Q. et al. Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials 53, 370–378 (2015).

  159. 159.

    Harrisson, S. et al. Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization. Angew. Chem. Int. Ed. 52, 1678–1682 (2013).

  160. 160.

    Liu, J. et al. Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles. Angew. Chem. Int. Ed. 54, 1002–1006 (2015).

  161. 161.

    Louage, B. et al. Well-defined polymer-paclitaxel prodrugs by a grafting-from-drug approach. Angew. Chem. Int. Ed. 55, 11791–11796 (2016). Drug-initiated in situ polymerization affords synthetically precise amphiphilic polymer–drug conjugates.

  162. 162.

    Zhang, H. & Grinstaff, M. W. Synthesis of atactic and isotactic poly(1,2-glycerol carbonate)s: degradable polymers for biomedical and pharmaceutical applications. J. Am. Chem. Soc. 135, 6806–6809 (2013).

  163. 163.

    Ekladious, I. et al. Synthesis of poly(1,2-glycerol carbonate)-paclitaxel conjugates and their utility as a single high-dose replacement for multi-dose treatment regimens in peritoneal cancer. Chem. Sci 8, 8443–8450 (2017). A high-drug-density, biodegradable polymer–drug conjugate nanocarrier exhibits sustained drug release, eliminating the need for frequent, repeated administrations of the small-molecule chemotherapeutic.

  164. 164.

    Geschwind, J. & Frey, H. Poly(1,2-glycerol carbonate): a fundamental polymer structure synthesized from CO2 and glycidyl ethers. Macromolecules 46, 3280–3287 (2013).

  165. 165.

    MacKay, J. A. et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater. 8, 993–999 (2009).

  166. 166.

    Kim, W. et al. Targeted antithrombotic protein micelles. Angew. Chem. Int. Ed. 54, 1461–1465 (2015).

  167. 167.

    Bhattacharyya, J. et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms abraxane in multiple murine cancer models. Nat. Commun. 6, 7939 (2015).

  168. 168.

    Zhang, S. et al. Poly(ethylene oxide)-block-polyphosphester-based paclitaxel conjugates as a platform for ultra-high paclitaxel-loaded multifunctional nanoparticles. Chem. Sci. 4, 2122–2126 (2013).

  169. 169.

    Ekladious, I. et al. Reinforcement of polymeric nanoassemblies for ultra-high drug loadings, modulation of stiffness and release kinetics, and sustained therapeutic efficacy. Nanoscale 10, 8360–8366 (2018).

  170. 170.

    Wilson, J. T. et al. pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 7, 3912–3925 (2013).

  171. 171.

    McDaniel, J. R. et al. Rational design of “heat seeking” drug loaded polypeptide nanoparticles that thermally target solid tumors. Nano Lett. 14, 2890–2895 (2014).

  172. 172.

    Zhou, K. et al. Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew. Chem. Int. Ed. 50, 6109–6114 (2011).

  173. 173.

    Zhang, Y. et al. Chain-shattering polymeric therapeutics with on-demand drug-release capability. Angew. Chem. Int. Ed. 52, 6435–6439 (2013).

  174. 174.

    Duan, X. et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 7, 5858–5869 (2013).

  175. 175.

    Tong, R. & Cheng, J. Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. Angew. Chem. Int. Ed. 47, 4830–4834 (2008).

  176. 176.

    Callari, M., De Souza, P. L., Rawal, A. & Stenzel, M. H. The effect of drug loading on micelle properties: solid-state NMR as a tool to gain structural insight. Angew. Chem. Int. Ed. 56, 8441–8445 (2017).

  177. 177.

    Namgung, R. et al. Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat. Commun. 5, 3702 (2014).

  178. 178.

    Mochida, Y. et al. Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor. ACS Nano 8, 6724–6738 (2014).

  179. 179.

    Benny, O. et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol. 26, 799–807 (2008). A polymer–drug conjugate nanoparticle affords oral bioavailability of the conjugated therapeutic, mitigating the neurotoxicity associated with systemic administration of the active agent.

  180. 180.

    Lee, U. Y. et al. Facile synthesis of multimeric micelles. Angew. Chem. Int. Ed. 51, 7287–7291 (2012).

  181. 181.

    Shen, Y. et al. Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J. Am. Chem. Soc. 132, 4259–4265 (2010). The self-assembly of polymer–drug conjugates into liposome-like nanocapsules enables the simultaneous encapsulation of a hydrophilic agent in the aqueous core.

  182. 182.

    Boott, C. E., Gwyther, J., Harniman, R. L., Hayward, D. W. & Manners, I. Scalable and uniform 1D nanoparticles by synchronous polymerization, crystallization and self-assembly. Nat. Chem. 9, 785–792 (2017).

  183. 183.

    Yang, M. et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. 50, 2597–2600 (2011).

  184. 184.

    Ahn, S. et al. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. J. Control. Release 170, 226–232 (2013).

  185. 185.

    Colson, Y. L. & Grinstaff, M. W. Biologically responsive polymeric nanoparticles for drug delivery. Adv. Mater. 24, 3878–3886 (2012).

  186. 186.

    Sprogoe, K., Mortensen, E., Karpf, D. B. & Leff, J. A. The rationale and design of transcon growth hormone for the treatment of growth hormone deficiency. Endocr. Connect. 6, R171–R181 (2017).

  187. 187.

    Gilfoyle, D., Mortensen, E., Christoffersen, E. D., Leff, J. A. & Beckert, M. A first-in-man phase 1 trial for long-acting TransCon Growth Hormone. Growth Horm. IGF Res. 39, 34–39 (2018).

  188. 188.

    Chan, J. M. et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl Acad. Sci. USA 107, 2213–2218 (2010).

  189. 189.

    Crielaard, B. J. et al. Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew. Chem. Int. Ed. 51, 7254–7258 (2012).

  190. 190.

    Peng, Z. H. & Kopecek, J. Enhancing accumulation and penetration of HPMA copolymer-doxorubicin conjugates in 2D and 3D prostate cancer cells via iRGD conjugation with an MMP-2 cleavable spacer. J. Am. Chem. Soc. 137, 6726–6729 (2015).

  191. 191.

    Miller, K., Erez, R., Segal, E., Shabat, D. & Satchi-Fainaro, R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. 48, 2949–2954 (2009).

  192. 192.

    Wang, T. et al. Intracellularly acid-switchable multifunctional micelles for combinational photo/chemotherapy of the drug-resistant tumor. ACS Nano 10, 3496–3508 (2016).

  193. 193.

    Zhu, L., Wang, T., Perche, F., Taigind, A. & Torchilin, V. P. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc. Natl Acad. Sci. USA 110, 17047–17052 (2013).

  194. 194.

    Pang, X. et al. pH-responsive polymer-drug conjugates: design and progress. J. Control. Release 222, 116–129 (2016).

  195. 195.

    Quan, L. D. et al. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res. Ther. 12, R170 (2010).

  196. 196.

    Zhu, S. et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 31, 1360–1371 (2010).

  197. 197.

    Du, J. Z., Du, X. J., Mao, C. Q. & Wang, J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 133, 17560–17563 (2011). The triggered switch of nanocarrier surface charge from positive to negative promotes cancer cell internalization.

  198. 198.

    Takahashi, A. et al. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci. 104, 920–925 (2013).

  199. 199.

    Mukai, H. et al. A first-in-human phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. Invest. New Drugs 35, 307–314 (2017).

  200. 200.

    Hu, X., Liu, G., Li, Y., Wang, X. & Liu, S. Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals. J. Am. Chem. Soc. 137, 362–368 (2015). Upon intracellular release of disulfide-linked camptothecin, a hydrophobic-to-hydrophilic transition of the nanocarrier polymer matrix enables the exchange of water for magnetic resonance imaging.

  201. 201.

    Luo, C. et al. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 16, 5401–5408 (2016).

  202. 202.

    Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008).

  203. 203.

    Arroyo-Crespo, J. J. et al. Anticancer activity driven by drug linker modification in a polyglutamic acid-based combination-drug conjugate. Adv. Funct. Mater. 28, 13 (2018).

  204. 204.

    Tong, R., Hemmati, H. D., Langer, R. & Kohane, D. S. Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J. Am. Chem. Soc. 134, 8848–8855 (2012).

  205. 205.

    Li, H. J. et al. Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano 10, 6753–6761 (2016). Upon exposure to the mildly acidic tumour microenvironment, trigger-responsive nanoassemblies dissociate into smaller dendrimer components, enabling the optimization of both plasma half-life and tumour penetration.

  206. 206.

    Beck, A., Goetsch, L., Dumontet, C. & Corvaia, N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).

  207. 207.

    Yang, J. & Kopecek, J. The light at the end of the tunnel-second generation HPMA conjugates for cancer treatment. Curr. Opin. Colloid Interface Sci 31, 30–42 (2017).

  208. 208.

    Seymour, L. W. et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20, 1668–1676 (2002).

  209. 209.

    Duncan, R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv. Drug Deliv. Rev. 61, 1131–1148 (2009).

  210. 210.

    Williams, R. Discontinued drugs in 2008: oncology drugs. Expert Opin. Investig. Drugs 18, 1581–1594 (2009).

  211. 211.

    Xu, H. et al. Targeted polymer-drug conjugates: current progress and future perspective. Colloids Surf. B Biointerfaces 136, 729–734 (2015).

  212. 212.

    Yao, V. J. et al. Ligand-targeted theranostic nanomedicines against cancer. J. Control. Release 240, 267–286 (2016).

  213. 213.

    Srinivasarao, M. & Low, P. S. Ligand-targeted drug delivery. Chem. Rev. 117, 12133–12164 (2017).

  214. 214.

    Miura, Y. et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 7, 8583–8592 (2013).

  215. 215.

    Oh, S. S. et al. Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cells. J. Am. Chem. Soc. 136, 15010–15015 (2014).

  216. 216.

    Park, J. et al. Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers. ACS Nano 8, 3347–3356 (2014).

  217. 217.

    Lee, H., Dellatore, S. M., Miller, W. M. & Messersmith, P. B. Mussel-inspired surface chemistry for multifunctional coatings. Science 318, 426–430 (2007).

  218. 218.

    Wei, X. et al. A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew. Chem. Int. Ed. 54, 3023–3027 (2015).

  219. 219.

    Zhang, C. et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease mice. Biomaterials 35, 456–465 (2014).

  220. 220.

    Morris, C. J., Smith, M. W., Griffiths, P. C., McKeown, N. B. & Gumbleton, M. Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. J. Control. Release 151, 83–94 (2011).

  221. 221.

    Ma, K. et al. Pamam-triamcinolone acetonide conjugate as a nucleus-targeting gene carrier for enhanced transfer activity. Biomaterials 30, 6109–6118 (2009).

  222. 222.

    Cuchelkar, V., Kopeckova, P. & Kopecek, J. Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. Mol. Pharm. 5, 776–786 (2008).

  223. 223.

    Greco, F. & Vicent, M. J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61, 1203–1213 (2009).

  224. 224.

    Conway, D. & Cohen, J. A. Combination therapy in multiple sclerosis. Lancet Neurol. 9, 299–308 (2010).

  225. 225.

    Cahn, A. & Cefalu, W. T. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care 39, (Suppl. 2), S137–S145 (2016).

  226. 226.

    Tallarida, R. J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 298, 865–872 (2001).

  227. 227.

    Xiao, H. et al. Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. J. Control. Release 163, 304–314 (2012).

  228. 228.

    Aryal, S., Hu, C. M. & Zhang, L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharm. 8, 1401–1407 (2011).

  229. 229.

    Pathak, R. K. & Dhar, S. A nanoparticle cocktail: temporal release of predefined drug combinations. J. Am. Chem. Soc. 137, 8324–8327 (2015). A polymer–drug conjugate nanocarrier is developed for the concurrent delivery of a cocktail of therapeutic agents at predefined ratios and with differential release kinetics.

  230. 230.

    Luo, S. et al. Precise ratiometric control of dual drugs through a single macromolecule for combination therapy. Mol. Pharm. 12, 2318–2327 (2015).

  231. 231.

    Yuan, Y., Liu, J. & Liu, B. Conjugated-polyelectrolyte-based polyprodrug: targeted and image-guided photodynamic and chemotherapy with on-demand drug release upon irradiation with a single light source. Angew. Chem. Int. Ed. 53, 7163–7168 (2014). This report describes the rational design of a sophisticated multifunctional polymer therapeutic that enables targeted and image-guided chemotherapy, as well as photodynamic therapy.

  232. 232.

    Li, Y. et al. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat. Commun. 5, 4712 (2014).

  233. 233.

    Janib, S. M., Moses, A. S. & MacKay, J. A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62, 1052–1063 (2010).

  234. 234.

    Huang, C. H., Nwe, K., Al Zaki, A., Brechbiel, M. W. & Tsourkas, A. Biodegradable polydisulfide dendrimer nanoclusters as mri contrast agents. ACS Nano 6, 9416–9424 (2012).

  235. 235.

    Wang, Y. et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 13, 204–212 (2014).

  236. 236.

    Cheng, Z., Thorek, D. L. & Tsourkas, A. Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew. Chem. Int. Ed. 49, 346–350 (2010).

  237. 237.

    Wu, C. et al. Design of highly emissive polymer dot bioconjugates for in vivo tumor targeting. Angew. Chem. Int. Ed. 50, 3430–3434 (2011).

  238. 238.

    Rong, Y. et al. Multicolor fluorescent semiconducting polymer dots with narrow emissions and high brightness. ACS Nano 7, 376–384 (2013).

  239. 239.

    Li, X., Takashima, M., Yuba, E., Harada, A. & Kono, K. PEGylated pamam dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy. Biomaterials 35, 6576–6584 (2014).

  240. 240.

    Swierczewska, M., Lee, K. C. & Lee, S. What is the future of PEGylated therapies? Expert Opin. Emerg. Drugs 20, 531–536 (2015).

  241. 241.

    Zhang, P., Sun, F., Liu, S. & Jiang, S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J. Control. Release 244, 184–193 (2016).

  242. 242.

    Baumann, A., Tuerck, D., Prabhu, S., Dickmann, L. & Sims, J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov. Today 19, 1623–1631 (2014).

  243. 243.

    Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2017).

  244. 244.

    Prabhakar, U. et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412–2417 (2013).

  245. 245.

    Danhier, F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release 244, 108–121 (2016).

  246. 246.

    Hansen, A. E. et al. Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes. ACS Nano 9, 6985–6995 (2015).

  247. 247.

    Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

  248. 248.

    Miller, M. A. et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci. Transl Med. 7, 314ra183 (2015).

  249. 249.

    Fang, J., Nakamura, H. & Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136–151 (2011).

  250. 250.

    Arrieta, O. et al. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother. Pharmacol. 74, 211–215 (2014).

  251. 251.

    Ramanathan, R. K. et al. Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study. Clin. Cancer Res. 23, 3638–3648 (2017).

  252. 252.

    Lee, H. et al. 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin. Cancer Res. 23, 4190–4202 (2017).

  253. 253.

    Lee, H. et al. Companion diagnostic 64Cu-liposome positron emission tomography enables characterization of drug delivery to tumors and predicts response to cancer nanomedicines. Theranostics 8, 2300–2312 (2018).

  254. 254.

    Gabizon, A. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987–992 (1994).

  255. 255.

    Symon, Z. et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86, 72–78 (1999).

  256. 256.

    Lammers, T. et al. Cancer nanomedicine: is targeting our target? Nat. Rev. Mater. 1, 16069 (2016).

  257. 257.

    Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951 (2015).

  258. 258.

    MacEwan, S. R. & Chilkoti, A. From composition to cure: a systems engineering approach to anticancer drug carriers. Angew. Chem. Int. Ed. 56, 6712–6733 (2017).

  259. 259.

    Duncan, R. Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century. J. Drug Target. 25, 759–780 (2017).

  260. 260.

    Tsuchiya, K. et al. Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: longer survival with larger size tumors. Urology 55, 495–500 (2000).

  261. 261.

    Dijkgraaf, E. M. et al. A phase 1/2 study combining gemcitabine, PEGintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 6, 32228–32243 (2015).

  262. 262.

    Chen, X. et al. Extended PEGinterferon alfa-2a (pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J. Med. Virol. 86, 1705–1713 (2014).

  263. 263.

    Kosaka, Y. et al. Phase III placebo-controlled, double-blind, randomized trial of PEGfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support. Care Cancer 23, 1137–1143 (2015).

  264. 264.

    Freda, P. U. et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr. Pract. 21, 264–274 (2015).

  265. 265.

    Autrata, R. et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3 + retinopathy of prematurity in zone I and posterior zone II. Eur. J. Ophthalmol. 22, 687–694 (2012).

  266. 266.

    Mease, P. J. et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis. 73, 48–55 (2014).

  267. 267.

    Baraf, H. S. et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res. Ther. 15, R137 (2013).

  268. 268.

    Kieseier, B. C. et al. PEGinterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult. Scler. 21, 1025–1035 (2015).

  269. 269.

    Konkle, B. A. et al. PEGylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 126, 1078–1085 (2015).

  270. 270.

    Thomas, J. et al. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol. Genet. Metab. 124, 27–38 (2018).

  271. 271.

    Coyle, T. E. et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J. Thromb. Haemost. 12, 488–496 (2014).

  272. 272.

    Giangrande, P. et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb. Haemost. 117, 252–261 (2017).

  273. 273.

    Angiolillo, A. L. et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children’s Oncology Group Study AALL07P4. J. Clin. Oncol. 32, 3874–3882 (2014).

  274. 274.

    Bowser, J. L., Lee, J. W., Yuan, X. & Eltzschig, H. K. The hypoxia-adenosine link during inflammation. J. Appl. Physiol. 123, 1303–1320 (2017).

  275. 275.

    Hingorani, S. R. et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 36, 359–366 (2018).

  276. 276.

    Szlosarek, P. W. et al. Arginine deprivation with PEGylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol. 3, 58–66 (2017).

  277. 277.

    Mussai, F. et al. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood 125, 2386–2396 (2015).

  278. 278.

    Sands, E., Kivitz, A. J., DeHaan, W., Johnston, L. & Kishimoto, T. K. Initial phase 2 clinical data of SEL-212 in symptomatic gout patients: monthly dosing of a PEGylated uricase (PEGsiticase) with SVP-rapamycin enables sustained reduction of serum uric acid levels by mitigating formation of anti-drug antibodies. Arthritis Rheumatol. 69, 2 (2017).

  279. 279.

    Misra, H., Lickliter, J., Kazo, F. & Abuchowski, A. PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial. Artif. Organs 38, 702–707 (2014).

  280. 280.

    Burrage, L. C. et al. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. Hum. Mol. Genet. 24, 6417–6427 (2015).

  281. 281.

    Chamberlain, C. et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann. Rheum. Dis. 76, 1837–1844 (2017).

  282. 282.

    Drolet, D. W., Green, L. S., Gold, L. & Janjic, N. Fit for the eye: aptamers in ocular disorders. Nucleic Acid. Ther. 26, 127–146 (2016).

  283. 283.

    Chhabra, E. S. et al. Evaluation of enhanced in vitro plasma stability of a novel long acting recombinant FVIIIFc-VWF-XTEN fusion protein. Blood 126, 3 (2015).

  284. 284.

    Ludwig, H. et al. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a phase IIa study. Leukemia 31, 997–1000 (2017).

  285. 285.

    Jaffe, G. J. et al. A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology 123, 78–85 (2016).

  286. 286.

    Chen, X. et al. Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients. J. Diabetes 9, 158–167 (2017).

  287. 287.

    Plummer, R. et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104, 593–598 (2011).

  288. 288.

    Paz-Ares, L. et al. Phase III trial comparing paclitaxel poliglumex versus docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer 98, 1608–1613 (2008).

  289. 289.

    Pham, E. et al. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin. Cancer Res. 21, 808–818 (2015).

  290. 290.

    Hamaguchi, T. et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 16, 5058–5066 (2010).

  291. 291.

    Thellenberg-Karlsson, C. et al. Bone-targeted novel cytotoxic polybisphosphonate conjugate in castration-resistant prostate cancer: a multicenter phase 1 study. Anticancer Res. 36, 6499–6504 (2016).

  292. 292.

    Liu, Z., Marquez, M., Nilsson, S. & Holmberg, A. R. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol. Rep. 20, 151–154 (2008).

  293. 293.

    Fares, F., Azzam, N., Fares, B., Larsen, S. & Lindkaer-Jensen, S. Benzene-poly-carboxylic acid complex, a novel anti-cancer agent induces apoptosis in human breast cancer cells. PLOS ONE 9, e85156 (2014).

  294. 294.

    Starpharma Holdings Limited. Starpharma to commence DEP® cabazitaxel phase 1/2 trial. Starpharma http://www.starpharma.com/news/356 (2018).

  295. 295.

    Bhasi, K. et al. Modeling suggests synergistic treatment effect following combination therapy of NKTR-214 and NKTR-262 in tumor bearing mice. J. Pharmacokinet. Pharmacodyn. 44, S89 (2017).

  296. 296.

    Ueno, T. et al. Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016). Int. J. Nanomed. 9, 3005–3012 (2014).

  297. 297.

    Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl Med. 1, 10–29 (2016).

  298. 298.

    Eskow Jaunarajs, K. L. et al. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. Mov. Disord. 28, 1675–1682 (2013).

  299. 299.

    Santi, D. V., Schneider, E. L. & Ashley, G. W. Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation. J. Med. Chem. 57, 2303–2314 (2014).

Download references

Acknowledgements

This work was supported in part by funding from the National Institutes of Health (R01EB017722, R01CA227433), the National Science Foundation (DGE-1247312 (I.E.), DMR-1507081), the Michael A. Bell Family Distinguished Chair in Healthcare Innovation at Brigham and Women’s Hospital (Y.L.C.) and the Distinguished Professor of Translational Research Chair at Boston University (M.W.G.).

Author information

Affiliations

  1. Departments of Biomedical Engineering, Chemistry, and Medicine, Boston University, Boston, MA, USA

    • Iriny Ekladious
    •  & Mark W. Grinstaff
  2. Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA

    • Yolonda L. Colson

Authors

  1. Search for Iriny Ekladious in:

  2. Search for Yolonda L. Colson in:

  3. Search for Mark W. Grinstaff in:

Competing interests

M.W.G. and I.E. are co-inventors on a patent application describing a new polymer for drug conjugation (US20170369643A1) owned by Boston University and available for license.

Corresponding authors

Correspondence to Yolonda L. Colson or Mark W. Grinstaff.

Glossary

Bioactives

Molecules that elicit a biological response.

Excipient

A non-active substance formulated with an active pharmaceutical ingredient to enhance physicochemical characteristics such as stability and solubility.

Opsonization

The process by which foreign materials are coated with opsonin proteins to enhance their phagocytic uptake and clearance.

Semi-telechelic

A polymer with one reactive end group.

Zwitterionic

An electrically neutral molecule with at least one positive and one negative functional group.

Biodistribution

The distribution of a molecule within the body.

AUC

The area under the plasma drug concentration versus time curve. Larger AUC values are indicative of increased drug exposure.

C max

The maximal concentration of drug achieved after administration.

Therapeutic index

The ratio of the dose needed to elicit a toxic side effect relative to the dose needed to elicit a therapeutic effect. A larger therapeutic index is indicative of a safer drug.

Avidity

The cumulative strength of a binding interaction.

Theranostic

A system that combines therapeutic and imaging modalities for both treatment and diagnosis.

About this article

Publication history

Published

Issue Date

DOI

https://doi.org/10.1038/s41573-018-0005-0